Maze Therapeutics (MAZE) Depreciation & Amortization (CF) (2024 - 2026)

Maze Therapeutics has disclosed Depreciation & Amortization (CF) across 3 years of filings, most recently posting $444000.0 for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $444000.0, down 35.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.2 million (down 28.71% YoY), and the FY2025 annual result was $2.4 million, down 27.18% from the prior year.
• Depreciation & Amortization (CF) came in at $444000.0 for Q1 2026 at Maze Therapeutics, down from $499000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $950000.0 in Q1 2024 to a low of $444000.0 in Q1 2026.
• The 3-year median for Depreciation & Amortization (CF) is $684000.0 (2025), against an average of $683000.0.
• Across the five-year window, Depreciation & Amortization (CF) retreated 24.0% in 2025 and plunged 35.09% in 2026, its largest moves.
• Maze Therapeutics' Depreciation & Amortization (CF) stood at $708000.0 in 2024, then fell by 29.52% to $499000.0 in 2025, then dropped by 11.02% to $444000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $444000.0 (Q1 2026), $499000.0 (Q4 2025), and $571000.0 (Q3 2025), per Business Quant data.